search
Back to results

Study of ExoFlo for the Treatment of Perianal Fistulas

Primary Purpose

Perianal Fistula, Crohn's Disease

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ExoFlo
Local injection of normal saline
Sponsored by
Direct Biologics, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Perianal Fistula focused on measuring Perianal Fistula, Perianal Fistulizing Crohn's Disease

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Men and Women 18-75 years of age with a diagnosis of Crohn's Disease (CD) for at least six months duration. Single and/or Multi-tract Perianal fistula(s). Failed at least one medical therapy within the last year including, but not limited to, antibiotics, immunomodulators (6-MP, methotrexate, azathioprine), monoclonal antibodies (infliximab, adalimumab, certolizumab, ustekinumab, golimumab, vedolizumab), or small molecule inhibitors. Previous failed surgical intervention, including seton placement at least two weeks prior, or are not candidates for surgical intervention or are not willing to undergo surgical intervention for the management of their fistula. Medical therapy for CD stable for at least 2 months prior to administration of IMP. Changes in dosing or dosing intervals related to serum drug levels are permitted. Ability to comply with protocol. Competent and able to provide written informed consent. Exclusion Criteria: Active perianal abscess or infection at the time of screening, enrollment, or at the time of investigational product administration Clinically significant medical conditions within the six months before administration of IMP that would, in the opinion of the investigators, compromise the safety of the subject. History of cancer including melanoma (with the exception of localized skin cancers) within one year of screening. History of colorectal cancer within 2 years Subjects who have a diagnosis of coagulation disorders and/or are currently on anti-coagulant therapy Investigational drug within one month of treatment Pregnant or breast feeding or trying to become pregnant. Presence of a rectovaginal fistula Presence of an ileal anal pouch and/or history of proctectomy The presence of severe proctitis Any condition which, in the opinion of the investigator, would make it unsafe or unsuitable for patients to undergo Magnetic Resonance (MR) evaluations (i.e., presence of implantable or external MR unsafe device that cannot be removed, body weight exceeding limitations, claustrophobia etc.). A participant who is unwilling to use medically acceptable contraception methods during participation in study The following out of range laboratory results at screening (result may be repeated) WBC >11 x 109 /L Hemoglobin < 8 g/dl Platelet count <100,000/mL AST/ALT >2 times the upper limit of normal Creatinine >2 umol/L PT/INR: outside normal limits Hemoglobin A1c>6.5 mg/dL

Sites / Locations

  • Phillip Fleshner, MDRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Placebo Comparator

Placebo Comparator

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Cohort 1: Placebo

Cohort 2: Placebo

Cohort 3: Placebo

Cohort 1: Treatment

Cohort 2: Treatment

Cohort 3: Treatment

Arm Description

Local injection 15 mL of normal saline on Day 0

Local injection 30 mL of normal saline on Day 0

Local injection 30 mL of normal saline on Day 0 and Month 3

Local injection of 15 mL of ExoFlo on Day 0

Local injection of 30 mL of ExoFlo on Day 0

Local injection of 30 mL of ExoFlo on Day 0 and Month 3

Outcomes

Primary Outcome Measures

Safety and Feasibility
Safety will be defined as the rate of Adverse Events (AEs) or Severe Adverse Events (SAEs) related to IMP and administration of IMP in this patient population. Safety and feasibility will be evaluated for one dose of 15 mL or 30 mL ExoFlo or two doses of 30 mL ExoFlo in subjects with perianal fistula(s) in the setting of Crohn's Disease.

Secondary Outcome Measures

Healing
To evaluate the efficacy for one dose of 15 mL or 30 mL ExoFlo or two doses of 30 mL ExoFlo in subjects with perianal fistula(s) in the setting of Crohn's Disease. Subjects will be evaluated for healing progress: complete healing, partial healing, lack of response, or treatment failure.

Full Information

First Posted
April 19, 2023
Last Updated
August 31, 2023
Sponsor
Direct Biologics, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05836883
Brief Title
Study of ExoFlo for the Treatment of Perianal Fistulas
Official Title
A Phase IB/IIA Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Perianal Fistulizing Crohn's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 28, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Direct Biologics, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the safety and feasibility of ExoFlo as a treatment for Perianal Fistulizing Crohn's Disease.
Detailed Description
This is a phase IB/IIA, multicenter, single-blind, placebo-controlled, dose-escalation design, randomized controlled trial for the treatment of Perianal Fistulizing Crohn's Disease. Subjects will be randomized 2:1 Investigational Medicinal Product (IMP) to normal saline (NS) in 3 cohorts of 12 subjects as follows: Cohort 1: Local injection of 15 mL of IMP or NS on Day 0 (8 IMP, 4 NS) Cohort 2: Local injection of 30 mL of IMP or NS on Day 0 (8 IMP, 4 NS) Cohort 3: Local injection of 30 mL of IMP or NS on Day 0 and Month 3 (8 IMP, 4 NS)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Perianal Fistula, Crohn's Disease
Keywords
Perianal Fistula, Perianal Fistulizing Crohn's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Multicenter, Placebo-controlled, Dose-escalation Design, Randomized Controlled Trial.
Masking
Participant
Masking Description
Single-blind
Allocation
Randomized
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: Placebo
Arm Type
Placebo Comparator
Arm Description
Local injection 15 mL of normal saline on Day 0
Arm Title
Cohort 2: Placebo
Arm Type
Placebo Comparator
Arm Description
Local injection 30 mL of normal saline on Day 0
Arm Title
Cohort 3: Placebo
Arm Type
Placebo Comparator
Arm Description
Local injection 30 mL of normal saline on Day 0 and Month 3
Arm Title
Cohort 1: Treatment
Arm Type
Experimental
Arm Description
Local injection of 15 mL of ExoFlo on Day 0
Arm Title
Cohort 2: Treatment
Arm Type
Experimental
Arm Description
Local injection of 30 mL of ExoFlo on Day 0
Arm Title
Cohort 3: Treatment
Arm Type
Experimental
Arm Description
Local injection of 30 mL of ExoFlo on Day 0 and Month 3
Intervention Type
Biological
Intervention Name(s)
ExoFlo
Intervention Description
Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
Intervention Type
Other
Intervention Name(s)
Local injection of normal saline
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Safety and Feasibility
Description
Safety will be defined as the rate of Adverse Events (AEs) or Severe Adverse Events (SAEs) related to IMP and administration of IMP in this patient population. Safety and feasibility will be evaluated for one dose of 15 mL or 30 mL ExoFlo or two doses of 30 mL ExoFlo in subjects with perianal fistula(s) in the setting of Crohn's Disease.
Time Frame
12 Months
Secondary Outcome Measure Information:
Title
Healing
Description
To evaluate the efficacy for one dose of 15 mL or 30 mL ExoFlo or two doses of 30 mL ExoFlo in subjects with perianal fistula(s) in the setting of Crohn's Disease. Subjects will be evaluated for healing progress: complete healing, partial healing, lack of response, or treatment failure.
Time Frame
12 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and Women 18-75 years of age with a diagnosis of Crohn's Disease (CD) for at least six months duration. Single and/or Multi-tract Perianal fistula(s). Failed at least one medical therapy within the last year including, but not limited to, antibiotics, immunomodulators (6-MP, methotrexate, azathioprine), monoclonal antibodies (infliximab, adalimumab, certolizumab, ustekinumab, golimumab, vedolizumab), or small molecule inhibitors. Previous failed surgical intervention, including seton placement at least two weeks prior, or are not candidates for surgical intervention or are not willing to undergo surgical intervention for the management of their fistula. Medical therapy for CD stable for at least 2 months prior to administration of IMP. Changes in dosing or dosing intervals related to serum drug levels are permitted. Ability to comply with protocol. Competent and able to provide written informed consent. Exclusion Criteria: Active perianal abscess or infection at the time of screening, enrollment, or at the time of investigational product administration Clinically significant medical conditions within the six months before administration of IMP that would, in the opinion of the investigators, compromise the safety of the subject. History of cancer including melanoma (with the exception of localized skin cancers) within one year of screening. History of colorectal cancer within 2 years Subjects who have a diagnosis of coagulation disorders and/or are currently on anti-coagulant therapy Investigational drug within one month of treatment Pregnant or breast feeding or trying to become pregnant. Presence of a rectovaginal fistula Presence of an ileal anal pouch and/or history of proctectomy The presence of severe proctitis Any condition which, in the opinion of the investigator, would make it unsafe or unsuitable for patients to undergo Magnetic Resonance (MR) evaluations (i.e., presence of implantable or external MR unsafe device that cannot be removed, body weight exceeding limitations, claustrophobia etc.). A participant who is unwilling to use medically acceptable contraception methods during participation in study The following out of range laboratory results at screening (result may be repeated) WBC >11 x 109 /L Hemoglobin < 8 g/dl Platelet count <100,000/mL AST/ALT >2 times the upper limit of normal Creatinine >2 umol/L PT/INR: outside normal limits Hemoglobin A1c>6.5 mg/dL
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amy Lightner, MD
Phone
512-354-7124
Email
alightner@directbiologics.com
First Name & Middle Initial & Last Name or Official Title & Degree
Stephanie Cahill
Email
scahill@directbiologics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Lightner, MD
Organizational Affiliation
Direct Biologics, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Phillip Fleshner, MD
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gayane Ovsepyan, MPH
Email
Gayane.Ovsepyan@cshs.org
First Name & Middle Initial & Last Name & Degree
Phillip Fleshner, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://directbiologics.com/
Description
Direct Biologics, LLC

Learn more about this trial

Study of ExoFlo for the Treatment of Perianal Fistulas

We'll reach out to this number within 24 hrs